OXFORD, England — Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 32nd Annual Oppenheimer Healthcare Conference, taking place virtually from March 15th to 17th, 2022 and will hold a formal presentation in front of investors.

Beckley Psytech is excited to welcome the publication of a peer-reviewed literature review in the Journal of Psychopharmacology. The paper, entitled ‘A narrative synthesis of research with 5-MeO-DMT,’ explores the pharmacology, chemistry and metabolism of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), as well as epidemiological studies, and reported adverse and beneficial effects.